Fig. 2From: Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint resultsOpinions of the relative efficacy of 6 compared to 12 months of trastuzumab in various subsetsBack to article page